CannEpil Advances Toward Conditional FDA Approval for Dog Bone Cancer Pain
Oct 13, 2026
When your dog has bone cancer, finding ways to keep them comfortable can become one of your biggest priorities. A recent development offers a new treatment possibility to follow, although it does not change the options available today.
On October 5, 2026, Endovia Health Sciences and Lupvindol BioSciences announced that the FDA’s Center for Veterinary Medicine determined that CannEpil’s proposed use for controlling bone cancer pain in dogs qualifies as a minor use. This makes the investigational drug eligible to pursue the FDA’s conditional approval pathway. [1]
CannEpil has not received FDA approval or conditional approval. The announcement establishes a development pathway, rather than permission to sell the drug. [1]
What CannEpil is being developed to do
CannEpil is an investigational oral solution containing cannabidiol (CBD) and tetrahydrocannabinol (THC). The companies are developing it to control pain associated with bone cancer in dogs. [1]
The proposed use focuses on pain relief. This announcement does not establish that CannEpil treats the cancer itself, improves survival, or provides effective pain relief.
For families caring for a dog with cancer, that distinction matters. A potential future medicine deserves attention, while treatment decisions still need to reflect the evidence and options available now.
What conditional FDA approval means
The FDA’s Minor Use and Minor Species program supports drug development for relatively small animal populations. Dogs are a major species, but an uncommon condition in dogs can qualify as a minor use. [2]
Conditional approval requires a drug to meet applicable safety and manufacturing requirements and show a reasonable expectation of effectiveness. Full approval requires substantial evidence of effectiveness. [1,2]
If conditional approval is granted, the sponsor can market the drug for its labeled use while gathering the additional effectiveness evidence needed for full approval. Approval lasts one year, with up to four annual renewals if FDA requirements are met. [2]
Eligibility alone does not mean these requirements have been satisfied.
What happens next
According to the companies, a meeting with the FDA is scheduled for November 19, 2026, to discuss studies, manufacturing requirements, and regulatory submissions.
They are also preparing manufacturing capabilities in the United States, with a potential veterinary launch in 2027. That timeline depends on FDA review, completion of regulatory requirements, and manufacturing readiness. It is not a confirmed availability date. [1]
What this means for CBD and THC products
This milestone concerns a specific investigational medicine and proposed use. It does not establish that retail CBD oils, cannabis products, or human THC products are safe or effective substitutes.
The FDA cautions pet parents that it cannot ensure the safety or effectiveness of cannabis products marketed for animals and recommends discussing appropriate treatment options with a veterinarian. [3]
Do not use this announcement as a reason to add a cannabinoid product or change your dog’s prescribed medications on your own. If your dog has an adverse reaction after consuming cannabis, contact your veterinarian or an emergency veterinary hospital immediately. [3]
Questions to bring to your veterinarian
While researchers pursue new options, you can ask your veterinary team:
- How can we assess whether my dog’s current pain plan is helping?
- What changes should prompt a call or an urgent visit?
- What additional options can we consider if comfort is declining?
- Could any supplements or cannabinoid products interfere with my dog’s treatment?
- Are any relevant clinical trials currently available?
You do not need to wait for a future treatment to discuss your dog’s comfort today.
At Drake Dog Cancer Foundation, we understand how much hope new research can bring. This development is worth following, with clear expectations about what has been established and what still needs to happen. Your veterinary team can help you make decisions that support your dog’s comfort throughout their care.
References
- Endovia Health Sciences. (2026, October 5). Endovia and Lupvindol BioSciences announce FDA determination that CannEpil for canine bone cancer pain qualifies as a minor use, establishing eligibility for conditional approval pathway. Company news release, reproduced as Exhibit 99.1 in an SEC filing. https://www.sec.gov/Archives/edgar/data/1553788/000173112226001312/e7991_ex99-1.htm
- U.S. Food and Drug Administration. Conditional approval explained: A resource for veterinarians. Accessed October 13, 2026. https://www.fda.gov/animal-veterinary/resources-you/conditional-approval-explained-resource-veterinarians
- U.S. Food and Drug Administration. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). See “Pets and other Animals.” Accessed October 13, 2026. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
Reviewed by: Amber L. Drake, PhD
Â
Dr. Amber L. Drake is a board-certified holistic health practitioner, canine clinical herbalist, educator, and founder of the Drake Dog Cancer Foundation and Drake Dog Academy. She is dedicated to helping pet parents better understand canine cancer, treatment options, nutrition, quality of life, and supportive care through compassionate, evidence-informed education. Her work combines professional training, practical resources, and firsthand insight from supporting thousands of dog families through the challenges of a cancer diagnosis.
Â
Stay connected with news and updates!
Join our mailing list to receive the latest news and updates from our team.
Don't worry, your information will not be shared.
We hate SPAM. We will never sell your information, for any reason.
